Cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) is
one of the critical infectious complications related to host immune recovery. The spectrum of …

Cytomegalovirus (CMV) continues to be one of the most important pathogens that
universally affect solid organ and allogeneic hematopoietic stem cell transplant recipients …

Therapeutic T cells with desired specificity can be engineered by introducing T-cell
receptors (TCRs) specific for antigens of interest, such as those from pathogens or tumour …

Adoptive transfer of cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CMV-CTLs)
from original transplant donors or third-party donors was effective for the treatment of CMV …

Adoptive therapy with cytomegalovirus (CMV)‐specific cytotoxic T lymphocytes (CMV‐CTLs)
has emerged as an effective method for CMV infection. However, the efficacy reportedly …

Human cytomegalovirus reactivation is a major opportunistic infection after allogeneic
haematopoietic stem cell transplantation and has a complex relationship with post …

Ongoing trials to optimize CMV prophylaxis and treatment, and outcomes of HIV-to-HIV
organ transplantation in the United States, have significant implications to optimize …

Adoptive cell therapy using cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CMV-
CTLs) has demonstrated efficacy posttransplant. Despite the predicted limited engraftment of …

Cytomegalovirus (CMV) infections remain a major cause of morbidity and mortality after
allogeneic hematopoietic stem cell transplantation (HSCT), and standard antiviral therapies …

Haploidentical hematopoietic stem cell transplantation (h-HSCT) represents an efficient
curative approach for patients affected by hematologic malignancies in which the reduced …